Paradigm Biopharmaceuticals Ltd has released a press release.
Primary and Secondary endpoints met in MPS I Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- iPPS shows 3-year equivalent durability in OA Canine Study
- iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
- Phase 3 OA Trial to Proceed after Formal Safety Review
- PAR Receives Allowance for Key US Patent
- Paradigm CEO steps down & Appointment of MD
Later from Paradigm Biopharmaceuticals
- PAR Reports Phase 3 Clinical Trial Update
- 2023 Annual Report and Appendix 4E
- Ipps significant oa pain reduction at 12 months
- iPPS Increases Cartilage Thickness in Phase 2 Trial
- Paradigm Launches $30M Capital Raising
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals